{'fraction_non_alphanumeric': 0.045586107091172216, 'fraction_numerical': 0.03762662807525326, 'mean_word_length': 4.40234375, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Impact of anastrozole use on the prediction of final height in male adolescents: a retrospective cohort

Introduction: The objective of this study was to evaluate the impact of the use of anastrozole (ANZ) in monotherapy or associated with growth hormone (GH) in the predicted of final height (PFH) and nearfinal height (NFH) of male adolescents with PEF below target familiar height (TH). Methods: This is a retrospective cohort. Data were obtained from medical records in a pediatric endocrinology service. Results: 75 patients between 11 and 14 years old participated in this cohort. Treatment with ANZ occurred for 1 year in 38.7%, 2 years in 40.0%, and 3 years in 21.3%. 76.0% used GH+ANZ, and
24.0% ANZ alone. TH and PFH at different treatment times showed a statistically significant difference, regardless of the use or not of GH. The ANZ group alone showed a mean increase of 5.73cm, 7.60cm, and 7.15cm in predicted height after 1, 2, and 3 years of ANZ. In the GH+ANZ group, this increase was 6.82cm, 10.27cm, and 7.44cm. Twenty-seven patients reached NFH, and in these, we observed a statistically significant increase concerning baseline PFH of 4.68 cm in the total group and 5.55 cm in the GH+ANZ group. Conclusions: The use of ANZ effectively increased PFH and NFH in
adolescents with PFH below TH. However, the subgroup with concomitant use of GH had better
outcomes.